JMD ASIP MEMBERSHIP
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Originally published online as doi:10.2353/jmoldx.2007.070009 on July 9, 2007

Published online before print July 9, 2007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jmoldx.2007.070009v1
9/4/459    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ng, T. L.
Right arrow Articles by Horsman, D. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ng, T. L.
Right arrow Articles by Horsman, D. E.
Journal of Molecular Diagnostics 2007, Vol. 9, No. 4
Copyright © 2007 American Society for Investigative Pathology & Association for Molecular Pathology
DOI: 10.2353/jmoldx.2007.070009

Ewing Sarcoma with Novel Translocation t(2;16) Producing an In-Frame Fusion of FUS and FEV

Tony L. Ng*, Maureen J. O’Sullivan*, Catherine J. Pallen{dagger}, Malcolm Hayes{ddagger}, Paul W. Clarkson§, Mark Winstanley, Poul H.B. Sorensen*||, Torsten O. Nielsen* and Douglas E. Horsman{ddagger}

From the Department of Pathology and Laboratory Medicine, * University of British Columbia, Vancouver, British Columbia; the Department of Pediatrics, {dagger} Child and Family Research Institute, University of British Columbia, Vancouver; the Department of Pathology and Laboratory Medicine, {ddagger} British Columbia Cancer Agency, University of British Columbia, Vancouver; the Division of Surgical Oncology, § British Columbia Cancer Agency, Vancouver; the Department of Oncology, Hematology and BMT, British Columbia Children’s Hospital, Vancouver; and the Department of Molecular Oncology, || British Columbia Cancer Research Centre, University of British Columbia, Vancouver, British Columbia, Canada

Ewing family tumors are molecularly characterized by expression of chimeric transcripts generated by specific chromosomal translocations, most commonly involving fusion of the EWS gene to a member of the ETS family of transcription factors (including FLI1, ERG, ETV1, E1AF, and FEV). Approximately 85% of reported cases of Ewing sarcoma bear an EWS-FLI1 fusion. In rare cases, FUS can substitute for EWS, with translocation t(16;21)(p11;q24) producing a FUS-ERG fusion with no EWS rearrangement. We report a case of Ewing sarcoma, presenting as a pathological fracture of the distal clavicle in a 33-year-old male, in which cytogenetic analysis revealed a single t(2;16)(q35;p11) balanced translocation. Fluorescence in situ hybridization using a commercially available diagnostic probe was negative for an EWS gene rearrangement; instead, break-apart fluorescence in situ hybridization probes for FUS and FEV were positive for a translocation involving these genes. Cloning and sequencing of the breakpoint region demonstrated an in-frame fusion of FUS to FEV. In conclusion, this represents the first reported case of Ewing family tumors demonstrating a variant translocation involving FUS and FEV and highlights the need to consider alternative permutations of fusion partners for molecular diagnosis of sarcomas.




This article has been cited by other articles:


Home page
J. Mol. Diagn.Home page
F. G. Barr and R. B. Womer
Molecular Diagnosis of Ewing Family Tumors: Too Many Fusions... ?
J. Mol. Diagn., September 1, 2007; 9(4): 437 - 440.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Society for Investigative Pathology and the Association for Molecular Pathology.